Pharmacy Service Provider Agrees To Pay $2.75 Million To Resolve Allegations of CSA Violations, Fraud

Oops! Subscribers must be logged in to access this content.

Not A Controlled Substances’ Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the Controlled Substances Module.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson Controlled Substances Module, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Pharmacy Service Provider Agrees To Pay $2.75 Million To Resolve Allegations of CSA Violations, Fraud

Dennis Tosh

May 16, 2021 at 18:46:22 ET

A provider of pharmacy services to long-term care facilities has agreed to pay $2.75 million to resolve a range of allegations brought under the Controlled Substances Act (CSA) and the federal False Claims Act, including allegations that the company allowed opioids and other controlled substances to be dispensed without valid prescriptions (United States ex rel. Gharavi v. AlixaRx L... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Controlled Substances’ Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the Controlled Substances Module.

Subscription Benefits

Start Your Free Trial

Pharmacy Service Provider Agrees To Pay $2.75 Million To Resolve Allegations of CSA Violations, Fraud

My Research Folders

THOMPSON CONTROLLED SUBSTANCES

COMPLIANCE EXPERT

DEA RESOURCES

HELP

CONTACT